INTRODUCTION
The European Clinical Trials Directive 1 came into force on 1 May 2004. The directive made good clinical practice mandatory for all clinical drug trials, including academic trials, and not just commercial trials as previously.
The good clinical practice quality standard includes a large amount of paperwork, with documentation, monitoring, and audits, thereby increasing demands on resources. This demand raised a debate that predicted the decline or even disappearance of academic clinical research. 4 The dissatisfaction among academics was due to a general perception that the good clinical practice quality standard is bureaucratic and time consuming and does not ensure higher quality.
We 5 agreed with the electronic and paper files therefore we included the data from 2006 to guarantee uniformity. Two researchers (LB and CH) determined the rates of monitoring and publication for a random sample of approved academic clinical trials. Both researchers were trained to ensure good inter-rater agreement. Ratings by the Swedish and Norwegian competent authorities for drug approval were comparable.
We defined clinical applications from academic researchers on the basis of the data as well as the publication rights being the property of publicly employed researchers and the absence of a pharmaceutical company named on the first page of the trial protocol.
Clinical applications from the commercial sector were defined on the basis of a submission by a pharmaceutical company, a pharmaceutical company named on the first page of the trial protocol, or trial data or publication rights seeming to be the property of a pharmaceutical company. We classed those applications that did not fall into either category as nonclassifiable-for example, missing files or missing protocols.
We The median number of participants in academic, national and international (multicentre), trials did not change during the study period. The table also provides 10th and 90th centiles for these trials. The percentage of applications by academic researchers remained at about one third throughout the study ( figure) .
The Adherence to the directive was evaluated from the number of trials intended to be monitored; 89% were monitored in 2004 compared with 98% in 2005. Therefore non-adherence to the directive can be dismissed as a cause for lack of effect. The number of participants in academic trials did not noticeably increase despite the inclusion of a few international trials with substantial numbers. The decline therefore seems not to be a drift from many small trials to a few large ones. International academic trials were few but included more participants; it was not possible for us to identify how many of these participants were Danish, but they do not run into thousands.
A survey of investigator initiated trials at a major university hospital in Austria found a 66% decrease in academic research after the introduction of the Clinical Trials Directive whereas the sponsored trials remained constant. 6 Intermediary trends were observed in Norway and Sweden. This agrees with differences in the creation of an academic system for the good clinical practice quality standard.
A major difference between Denmark and Austria is that from about 2000 good clinical practice units were already established in Denmark, whereas such a system does not yet exist in Austria. In Denmark the universities and university hospitals fund good clinical practice units that provide free assistance to academic clinical researchers. The manpower invested is about five people per million population. We believe that such units and the focus on available expertise for the good clinical practice quality standard to academic researchers can explain the difference in trend of academic clinical research between Austria and Denmark.
We found no trials published earlier than four years after application; even during the observation period 1993-2006 no more than about 30% were published.
The reasons for this are unknown and need to be investigated by the relevant competent authorities.
We conclude that academic researchers can match the demands for the good clinical practice quality standard that industry have adhered to for many years, but only if universities and hospitals allocate resources to good clinical practice units. Allocation or redistribution of such relatively few resources is needed to prevent the decline in drug research and should be made before meeting the demands of more resources to academic drug research.
